AMSTERDAM, February 23, 2018 /PRNewswire/ --
Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic device, and key design rights are valid and infringed by AmplifEYE®. The patent and design rights had been challenged by Cantel Medical (UK) Limited and Cantel (UK) Limited.
(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )
Peter Martin, COO of Norgine and Chair of the Arc Medical Design Limited Board said: "We welcome the judgement and our resounding success, recognising the strong protection for both ENDOCUFF® and ENDOCUFF VISION®. This decision validates our confidence in the intellectual property portfolio protecting our products. We will always vigorously defend our intellectual property and will initiate legal proceedings where appropriate."
ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal.
Notes to Editors:
About the UK Case No. HP-2016-000047
On Friday 23 February 2018 the High Court of Justice England and Wales, Patents Court ruled that:Arc Medical Design Limited won on all counts:
View the full media release onhttp://www.norgine.com/media
Media Contact:
Isabelle Jouin, T: +44 (0)1895 453643
Follow us @norgine
